Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy
NCT06455826Phase 1Completed
- Sponsor
- PYC Therapeutics
- Start
- Jun 2024
- Primary completion
- Sep 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VP-001 in retinitis pigmentosa type 11 (RP11), sponsored by PYC Therapeutics. Primary endpoints: Incidence, severity, and relatedness of treatment-emergent ocular adverse events and treatment-emergent serious adverse events at 4 weeks and Incidence, severity, and relatedness of treatment-emergent ocular adverse events at 52 weeks. Started Jun 2024; status: completed.
02
Drugs
VP-001
03
Conditions
retinitis pigmentosa type 11 (RP11)
Beyond the preview
Go deeper on NCT06455826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06455826.